Mono Pharmacare (NSE:MONOPHARMA) Marketable Securities: ₹0 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MONOPHARMA Mono Pharmacare Ltd NSE:MONOPHARMA
11 GF Score
Price ₹8.65
! 6 Warning Signs
View Full Analysis

What is Mono Pharmacare Marketable Securities?

Mono Pharmacare NSE:MONOPHARMA 11 Marketable Securities is ₹0 Mil as of Sep. 2025. GuruFocus rates NSE:MONOPHARMA with a GF Score™ of 11/100. The stock has 6 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Mono Pharmacare's Marketable Securities for the quarter that ended in Sep. 2025 was ₹0 Mil.

Mono Pharmacare  (NSE:MONOPHARMA) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Mono Pharmacare Marketable Securities Related Terms

Mono Pharmacare Marketable Securities Historical Data

* Premium members only.

The historical data trend for Mono Pharmacare's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mono Pharmacare Marketable Securities Chart

Mono Pharmacare Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Marketable Securities
0.00 0.00 0.00 0.00 0.00

Mono Pharmacare Semi-Annual Data
Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Marketable Securities Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:MONOPHARMA
11GF Score
Mono Pharmacare Ltd NSE:MONOPHARMA
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mono Pharmacare Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of ₹0 Mil mean?
Mono Pharmacare (NSE:MONOPHARMA) has a Marketable Securities of ₹0 Mil as of Sep. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Mono Pharmacare and its competitors.
Is Mono Pharmacare's Marketable Securities too high?
Mono Pharmacare's current Marketable Securities is ₹0 Mil. Overall, Mono Pharmacare has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Mono Pharmacare's Marketable Securities compare to competitors?
Mono Pharmacare's Marketable Securities of ₹0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Healthcare Providers & Services company?
A good Marketable Securities depends on the Healthcare Providers & Services industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Mono Pharmacare and its competitors. Mono Pharmacare's current Marketable Securities is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mono Pharmacare stock overvalued right now?
Mono Pharmacare (NSE:MONOPHARMA) has a current Marketable Securities of ₹0 Mil. The current Marketable Securities is ₹0 Mil. Mono Pharmacare's overall GF Score™ is 11/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Mono Pharmacare (NSE:MONOPHARMA), the current Marketable Securities is ₹0 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mono Pharmacare Business Description

Address 1A, Krinkal Apartment, Opposite Mahalaxmi Temple, Paldi, Ahmedabad, GJ, IND, 380007
Mono Pharmacare Ltd distributes a broad range of pharmaceutical products across India. Its portfolio includes antibiotics, antifungal medicines, cough and cold remedies, antacids, analgesics, nutraceuticals, skincare, antiseptics, cardiac and diabetic drugs, and cosmetic items. The company operates through contract manufacturing, sourcing products from various manufacturers and supplying them to healthcare providers and pharmacies. Revenue is generated through the sales and distribution of these pharmaceutical and healthcare products in the Indian market.
11GF Score

Get the complete analysis for NSE:MONOPHARMA

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹8.65
Price